Leptomeningeal Carcinomatosis Clinical Trial
Official title:
Phase II Trial of Ipilimumab and Nivolumab in Leptomeningeal Metastases
This research study is studying a combination of two drugs as a possible treatment for Leptomeningeal Metastases. The names of the study interventions involved in this study are: - Ipilimumab - Nivolumab
This research study is a Phase II clinical trial. Researchers hope to study the effects of the combination of Nivolumab and Ipilimumab. Many cancers use specific pathways, such as programmed death-1 (PD-1), programmed death-ligand-1 (PD-L1), and cytotoxic T lymphocyte antigen-4 (CTLA-4), to evade the body's immune system. Nivolumab and ipilimumab work by blocking the PD-1/PD-L1 and CTLA-4 pathways and thus releasing the brakes on the immune system so it can stop or slow cancer. The FDA (the U.S. Food and Drug Administration) has approved Nivolumab and Ipilimumab as a treatment option for melanoma, but has not approved them for use when cancer cells spread to the cerebrospinal fluid ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00527410 -
A Safety Study of RTA 744 in Recurrent, Progressive or Refractory Neoplastic Meningitis
|
Phase 1 | |
| Terminated |
NCT00830245 -
A Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT03613181 -
ANG1005 in Leptomeningeal Disease From Breast Cancer
|
Phase 3 | |
| No longer available |
NCT02755987 -
Expanded Access to ANG1005 for Individual Patients
|
N/A |